Most Ditch GLP-1 Drugs for Weight Loss Within a Year
Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...
A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
However, Clinic Secret has emerged as a potential game-changer in weight loss by offering a clinically proven, accessible solution that leverages the power of GLP-1 medications. In this ...
News Medical on MSN9d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback